Advanced Urothelial Cancer
Cross-source consensus on Advanced Urothelial Cancer from 1 sources and 4 claims.
1 sources · 4 claims
Background
Where it comes from
Highlighted claims
- Cisplatin-based chemotherapy has historically been standard care for locally advanced or metastatic urothelial carcinoma. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- Bladder urothelial carcinoma is the 11th most common cancer overall in the UK and the ninth leading cause of cancer-related death. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- The treatment landscape for advanced urothelial cancer has changed because of immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
- Urothelial carcinoma is clinically and economically important in the UK. — Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom